Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HINT1 | P49773 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | KRAS | P01116 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744021 | 1.00 | HPGD (0.54) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL3918431 | 1.00 | HPGD (0.54) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL25758010 | 0.91 | HPGD (0.54) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL7614834 | 0.91 | HPGD (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL7614827 | 0.91 | HPGD (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL26194 | 0.89 | HPGD (0.57) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL28805008 | 0.89 | HPGD (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL23928737 | 0.88 | HPGD (0.56) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL27351 | 0.88 | HINT1 (0.59) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL315459 | 0.88 | HPGD (0.56) | HPGDHINT1NT5ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569685-B2 | Artificial RNAóS modified at the 2ó-hydroxyl group | JAPAN SCIENCCE AND TECHNOLOGY AGENCY (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080021206-A1 | Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021206-A1 | Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group | FBL, NSUN2, METTL16 | HPGD 2770/4885HINT1 1075/4885NT5E 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.